These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34043697)

  • 1. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
    PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH; Freier S; Shor R; Farzam N; Block C; Lison M; Shiff E; Ashkenazi S
    Pediatr Infect Dis J; 1995 Oct; 14(10):859-65. PubMed ID: 8584312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis.
    Ndungo E; Andronescu LR; Buchwald AG; Lemme-Dumit JM; Mawindo P; Kapoor N; Fairman J; Laufer MK; Pasetti MF
    Front Immunol; 2021; 12():725129. PubMed ID: 34721387
    [No Abstract]   [Full Text] [Related]  

  • 7. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
    Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH; Ashkenazi S; Banet-Levi Y; Ramon-Saraf R; Farzam N; Lerner-Geva L; Even-Nir H; Yerushalmi B; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Vaccine; 2010 Mar; 28(10):2231-2235. PubMed ID: 20056180
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
    Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
    Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
    Leroux-Roels I; Maes C; Mancini F; Jacobs B; Sarakinou E; Alhatemi A; Joye J; Grappi S; Cilio GL; Serry-Bangura A; Vitali CG; Ferruzzi P; Marchetti E; Necchi F; Rappuoli R; De Ryck I; Auerbach J; Colucci AM; Rossi O; Conti V; Scorza FB; Arora AK; Micoli F; Podda A; Nakakana UN;
    J Infect Dis; 2024 Oct; 230(4):e971-e984. PubMed ID: 38853614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function.
    Bernshtein B; Kelly M; Cizmeci D; Zhiteneva JA; Macvicar R; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; Qadri F; Charles RC; Xu P; Kováč P; Clarkson KA; Kaminski RW; Alter G; Ryan ET
    Lancet Microbe; 2024 Oct; 5(10):100889. PubMed ID: 39116906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M; Janardhanan J; Wagh C; Verma S; Charles RC; Leung DT; Kamruzzaman M; Pansuriya RK; Chowdhury F; Vann WF; Kaminski RW; Khan AI; Bhuiyan TR; Qadri F; Kováč P; Xu P; Ryan ET
    Vaccine; 2024 Oct; 42(24):126263. PubMed ID: 39217775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.